SpringWorks Therapeutics Announces Presentation Of Additional Data From Phase 3 DeFi Trial Of Nirogacestat In Adults With Desmoid Tumors At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics announced additional data from its Phase 3 DeFi trial of Nirogacestat in adults with desmoid tumors at the 2023 ASCO Meeting. The treatment demonstrated rapid, sustained, and consistent reductions in pain compared to placebo, as well as substantial reductions in MRI-assessed tumor volume and T2 hyperintensity.
May 25, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SpringWorks Therapeutics' Nirogacestat showed positive results in Phase 3 DeFi trial for desmoid tumor treatment, potentially boosting the company's stock price.
The positive results from the Phase 3 DeFi trial of Nirogacestat indicate that the drug is effective in treating desmoid tumors. This could lead to increased demand for the drug and higher revenues for SpringWorks Therapeutics, which may positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100